"Canagliflozin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
| Descriptor ID |
D000068896
|
| MeSH Number(s) |
D02.886.778.075 D03.383.903.075 D09.408.348.113
|
| Concept/Terms |
Canagliflozin- Canagliflozin
- Canagliflozin Hemihydrate
- Hemihydrate, Canagliflozin
Canagliflozin, Anhydrous- Canagliflozin, Anhydrous
- Anhydrous Canagliflozin
- 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
|
Below are MeSH descriptors whose meaning is more general than "Canagliflozin".
Below are MeSH descriptors whose meaning is more specific than "Canagliflozin".
This graph shows the total number of publications written about "Canagliflozin" by people in this website by year, and whether "Canagliflozin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 3 | 3 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 1 | 5 |
| 2021 | 2 | 2 | 4 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Canagliflozin" by people in Profiles.
-
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes Obes Metab. 2023 05; 25(5):1413-1418.
-
Cardiovascular Effects of Canagliflozin in?Relation to Renal Function and?Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.
-
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With?Diabetes and Chronic Kidney Disease:?A?Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc. 2022 08 16; 11(16):e025045.
-
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 06 23; 37(7):1261-1269.
-
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metab. 2022 07; 48(4):101331.
-
Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. Clin J Am Soc Nephrol. 2022 03; 17(3):361-373.
-
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 12 21; 42(48):4891-4901.
-
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial. Diabetes Obes Metab. 2021 07; 23(7):1652-1659.
-
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
-
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial. Circulation. 2021 05 04; 143(18):1735-1749.